96 related articles for article (PubMed ID: 25527175)
1. Characterization of the 19q12 amplification including CCNE1 and URI in different epithelial ovarian cancer subtypes.
Noske A; Henricksen LA; LaFleur B; Zimmermann AK; Tubbs A; Singh S; Storz M; Fink D; Moch H
Exp Mol Pathol; 2015 Feb; 98(1):47-54. PubMed ID: 25527175
[TBL] [Abstract][Full Text] [Related]
2. Functional characterization of the 19q12 amplicon in grade III breast cancers.
Natrajan R; Mackay A; Wilkerson PM; Lambros MB; Wetterskog D; Arnedos M; Shiu KK; Geyer FC; Langerød A; Kreike B; Reyal F; Horlings HM; van de Vijver MJ; Palacios J; Weigelt B; Reis-Filho JS
Breast Cancer Res; 2012 Mar; 14(2):R53. PubMed ID: 22433433
[TBL] [Abstract][Full Text] [Related]
3. High cyclin E1 protein, but not gene amplification, is prognostic for basal-like breast cancer.
Aziz D; Lee C; Chin V; Fernandez KJ; Phan Z; ; ; Waring P; Caldon CE
J Pathol Clin Res; 2022 Jul; 8(4):355-370. PubMed ID: 35384378
[TBL] [Abstract][Full Text] [Related]
4. CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.
Kang EY; Weir A; Meagher NS; Farrington K; Nelson GS; Ghatage P; Lee CH; Riggan MJ; Bolithon A; Popovic G; Leung B; Tang K; Lambie N; Millstein J; Alsop J; Anglesio MS; Ataseven B; Barlow E; Beckmann MW; Berger J; Bisinotto C; Bösmüller H; Boros J; Brand AH; Brooks-Wilson A; Brucker SY; Carney ME; Casablanca Y; Cazorla-Jiménez A; Cohen PA; Conrads TP; Cook LS; Coulson P; Courtney-Brooks M; Cramer DW; Crowe P; Cunningham JM; Cybulski C; Darcy KM; El-Bahrawy MA; Elishaev E; Erber R; Farrell R; Fereday S; Fischer A; García MJ; Gayther SA; Gentry-Maharaj A; Gilks CB; ; Grube M; Harnett PR; Harrington SP; Harter P; Hartmann A; Hecht JL; Heikaus S; Hein A; Heitz F; Hendley J; Hernandez BY; Polo SH; Heublein S; Hirasawa A; Høgdall E; Høgdall CK; Horlings HM; Huntsman DG; Huzarski T; Jewell A; Jimenez-Linan M; Jones ME; Kaufmann SH; Kennedy CJ; Khabele D; Kommoss FKF; Kruitwagen RFPM; Lambrechts D; Le ND; Lener M; Lester J; Leung Y; Linder A; Loverix L; Lubiński J; Madan R; Maxwell GL; Modugno F; Neuhausen SL; Olawaiye A; Olbrecht S; Orsulic S; Palacios J; Pearce CL; Pike MC; Quinn CM; Mohan GR; Rodríguez-Antona C; Ruebner M; Ryan A; Salfinger SG; Sasamoto N; Schildkraut JM; Schoemaker MJ; Shah M; Sharma R; Shvetsov YB; Singh N; Sonke GS; Steele L; Stewart CJR; Sundfeldt K; Swerdlow AJ; Talhouk A; Tan A; Taylor SE; Terry KL; Tołoczko A; Traficante N; Van de Vijver KK; van der Aa MA; Van Gorp T; Van Nieuwenhuysen E; van-Wagensveld L; Vergote I; Vierkant RA; Wang C; Wilkens LR; Winham SJ; Wu AH; Benitez J; Berchuck A; Candido Dos Reis FJ; DeFazio A; Fasching PA; Goode EL; Goodman MT; Gronwald J; Karlan BY; Kommoss S; Menon U; Sinn HP; Staebler A; Brenton JD; Bowtell DD; Pharoah PDP; Ramus SJ; Köbel M
Cancer; 2023 Mar; 129(5):697-713. PubMed ID: 36572991
[TBL] [Abstract][Full Text] [Related]
5. Reduced RBX1 expression induces chromosome instability and promotes cellular transformation in high-grade serous ovarian cancer precursor cells.
Bungsy M; Palmer MCL; Jeusset LM; Neudorf NM; Lichtensztejn Z; Nachtigal MW; McManus KJ
Cancer Lett; 2021 Mar; 500():194-207. PubMed ID: 33290867
[TBL] [Abstract][Full Text] [Related]
6.
Kawahara N; Yamada Y; Kobayashi H
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070839
[TBL] [Abstract][Full Text] [Related]
7. Reduced SKP1 and CUL1 expression underlies increases in Cyclin E1 and chromosome instability in cellular precursors of high-grade serous ovarian cancer.
Lepage CC; Palmer MCL; Farrell AC; Neudorf NM; Lichtensztejn Z; Nachtigal MW; McManus KJ
Br J Cancer; 2021 May; 124(10):1699-1710. PubMed ID: 33731859
[TBL] [Abstract][Full Text] [Related]
8. GCN-5/PGC-1α signaling is activated and associated with metabolism in cyclin E1-driven ovarian cancer.
Guo T; Li B; Gu C; Chen X; Han M; Liu X; Xu C
Aging (Albany NY); 2019 Jul; 11(14):4890-4899. PubMed ID: 31313989
[TBL] [Abstract][Full Text] [Related]
9. PTEN Deficiency in Tubo-Ovarian High-Grade Serous Carcinoma is Associated with Poor Progression-Free Survival and is Mutually Exclusive with CCNE1 Amplification.
Zhang X; Wang A; Han L; Liang B; Allard G; Diver E; Howitt BE
Mod Pathol; 2023 May; 36(5):100106. PubMed ID: 36805789
[TBL] [Abstract][Full Text] [Related]
10. CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition.
Gallo D; Young JTF; Fourtounis J; Martino G; Álvarez-Quilón A; Bernier C; Duffy NM; Papp R; Roulston A; Stocco R; Szychowski J; Veloso A; Alam H; Baruah PS; Fortin AB; Bowlan J; Chaudhary N; Desjardins J; Dietrich E; Fournier S; Fugère-Desjardins C; Goullet de Rugy T; Leclaire ME; Liu B; Bhaskaran V; Mamane Y; Melo H; Nicolas O; Singhania A; Szilard RK; Tkáč J; Yin SY; Morris SJ; Zinda M; Marshall CG; Durocher D
Nature; 2022 Apr; 604(7907):749-756. PubMed ID: 35444283
[TBL] [Abstract][Full Text] [Related]
11. Acrylamide and Glycidamide Hemoglobin Adducts and Epithelial Ovarian Cancer: A Nested Case-Control Study in Nonsmoking Postmenopausal Women from the EPIC Cohort.
Obón-Santacana M; Lujan-Barroso L; Travis RC; Freisling H; Ferrari P; Severi G; Baglietto L; Boutron-Ruault MC; Fortner RT; Ose J; Boeing H; Menéndez V; Sánchez-Cantalejo E; Chamosa S; Castaño JM; Ardanaz E; Khaw KT; Wareham N; Merritt MA; Gunter MJ; Trichopoulou A; Papatesta EM; Klinaki E; Saieva C; Tagliabue G; Tumino R; Sacerdote C; Mattiello A; Bueno-de-Mesquita HB; Peeters PH; Onland-Moret NC; Idahl A; Lundin E; Weiderpass E; Vesper HW; Riboli E; Duell EJ
Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):127-34. PubMed ID: 26598536
[TBL] [Abstract][Full Text] [Related]
12. The 19q12 bladder cancer GWAS signal: association with cyclin E function and aggressive disease.
Fu YP; Kohaar I; Moore LE; Lenz P; Figueroa JD; Tang W; Porter-Gill P; Chatterjee N; Scott-Johnson A; Garcia-Closas M; Muchmore B; Baris D; Paquin A; Ylaya K; Schwenn M; Apolo AB; Karagas MR; Tarway M; Johnson A; Mumy A; Schned A; Guedez L; Jones MA; Kida M; Hosain GM; Malats N; Kogevinas M; Tardon A; Serra C; Carrato A; Garcia-Closas R; Lloreta J; Wu X; Purdue M; Andriole GL; Grubb RL; Black A; Landi MT; Caporaso NE; Vineis P; Siddiq A; Bueno-de-Mesquita HB; Trichopoulos D; Ljungberg B; Severi G; Weiderpass E; Krogh V; Dorronsoro M; Travis RC; Tjønneland A; Brennan P; Chang-Claude J; Riboli E; Prescott J; Chen C; De Vivo I; Govannucci E; Hunter D; Kraft P; Lindstrom S; Gapstur SM; Jacobs EJ; Diver WR; Albanes D; Weinstein SJ; Virtamo J; Kooperberg C; Hohensee C; Rodabough RJ; Cortessis VK; Conti DV; Gago-Dominguez M; Stern MC; Pike MC; Van Den Berg D; Yuan JM; Haiman CA; Cussenot O; Cancel-Tassin G; Roupret M; Comperat E; Porru S; Carta A; Pavanello S; Arici C; Mastrangelo G; Grossman HB; Wang Z; Deng X; Chung CC; Hutchinson A; Burdette L; Wheeler W; Fraumeni J; Chanock SJ; Hewitt SM; Silverman DT; Rothman N; Prokunina-Olsson L
Cancer Res; 2014 Oct; 74(20):5808-18. PubMed ID: 25320178
[TBL] [Abstract][Full Text] [Related]
13. Inflammatory Markers and Risk of Epithelial Ovarian Cancer by Tumor Subtypes: The EPIC Cohort.
Ose J; Schock H; Tjønneland A; Hansen L; Overvad K; Dossus L; Clavel-Chapelon F; Baglietto L; Boeing H; Trichopolou A; Benetou V; Lagiou P; Masala G; Tagliabue G; Tumino R; Sacerdote C; Mattiello A; Bueno-de-Mesquita HB; Peeters PH; Onland-Moret NC; Weiderpass E; Gram IT; Sánchez S; Obon-Santacana M; Sànchez-Pérez MJ; Larrañaga N; Castaño JM; Ardanaz E; Brändstedt J; Lundin E; Idahl A; Travis RC; Khaw KT; Rinaldi S; Romieu I; Merritt MA; Gunter MJ; Riboli E; Kaaks R; Fortner RT
Cancer Epidemiol Biomarkers Prev; 2015 Jun; 24(6):951-61. PubMed ID: 25855626
[TBL] [Abstract][Full Text] [Related]
14.
Xu H; George E; Kinose Y; Kim H; Shah JB; Peake JD; Ferman B; Medvedev S; Murtha T; Barger CJ; Devins KM; D'Andrea K; Wubbenhorst B; Schwartz LE; Hwang WT; Mills GB; Nathanson KL; Karpf AR; Drapkin R; Brown EJ; Simpkins F
Cell Rep Med; 2021 Sep; 2(9):100394. PubMed ID: 34622231
[No Abstract] [Full Text] [Related]
15. Transcriptional analysis of multiple ovarian cancer cohorts reveals prognostic and immunomodulatory consequences of ERV expression.
Natoli M; Gallon J; Lu H; Amgheib A; Pinato DJ; Mauri FA; Marafioti T; Akarca AU; Ullmo I; Ip J; Aboagye EO; Brown R; Karadimitris A; Ghaem-Maghami S
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33436485
[TBL] [Abstract][Full Text] [Related]
16. Molecular Landscape and Clinical Implication of CCNE1-amplified Esophagogastric Cancer.
Rustgi N; Wu S; Samec T; Walker P; Xiu J; Lou E; Goel S; Saeed A; Moy RH
Cancer Res Commun; 2024 Jun; 4(6):1399-1409. PubMed ID: 38717153
[TBL] [Abstract][Full Text] [Related]
17. Targeting Therapeutic Resistance and Multinucleate Giant Cells in CCNE1-Amplified HR-Proficient Ovarian Cancer.
Bai S; Taylor SE; Jamalruddin MA; McGonigal S; Grimley E; Yang D; Bernstein KA; Buckanovich RJ
Mol Cancer Ther; 2022 Sep; 21(9):1473-1484. PubMed ID: 35732503
[TBL] [Abstract][Full Text] [Related]
18. Role of Genetic Variations in
Híveš M; Jurečeková J; Kliment J; Grendár M; Kaplán P; Dušenka R; Evin D; Vilčková M; Holečková KH; Sivoňová MK
Cancer Genomics Proteomics; 2022; 19(3):362-371. PubMed ID: 35430569
[TBL] [Abstract][Full Text] [Related]
19. A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome.
Vargas HA; Veeraraghavan H; Micco M; Nougaret S; Lakhman Y; Meier AA; Sosa R; Soslow RA; Levine DA; Weigelt B; Aghajanian C; Hricak H; Deasy J; Snyder A; Sala E
Eur Radiol; 2017 Sep; 27(9):3991-4001. PubMed ID: 28289945
[TBL] [Abstract][Full Text] [Related]
20. Targeted and Shallow Whole-Genome Sequencing Identifies Therapeutic Opportunities in p53abn Endometrial Cancers.
Jamieson A; Sobral de Barros J; Cochrane DR; Douglas JM; Shankar S; Lynch BJ; Leung S; Martin S; Senz J; Lum A; Drew Y; Gilks CB; Huntsman DG; McAlpine JN
Clin Cancer Res; 2024 Jun; 30(11):2461-2474. PubMed ID: 38536067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
